Novartis   4Q Revenues: $15.1 billion (+2%) 4Q Earnings: $3.0 billion (-3%) FY Revenues: $57.9 billion (+2%) FY Earnings: $12.5 billion (flat) Comments: Pharmaceutical sales were $8.3 billion in the quarter, up 1%, with growth products contributing $4.8 billion or 32% of group sales, up 15%, offset by the impact of generic competition for Zometa/Aclasta and Diovan. Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, the Q Family[2] and Jakavi, generated $3.3 billion in sales, or 40% of div...